Zusammenfassung
Die Entwicklung von IgG-Antikörpern gegen substituierten Faktor VIII: C, bleibt trotz der vielen neuen Erkenntnisse auf dem Gebiet ihrer molekularbiologischen Eigenschaften weiterhin ein gravierendes und bisher ungelöstes Problem der Hämophiliebehandlung.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Biggs R (1974) Jaundice and antibodies directed against factors VIII and IX in patients treated for haemophilia or Christmas disease in the United Kingdom. Br J Haematol 26:313–329
Brinkhous KM, Roberts HR, Weiss AE (1972) Prevalence of inhibitors in hemophilia A and B. Thromb Diath Haemorrh Suppl 51:315–321
Gill FM, Shapiro SS, Poole WK.et al (1984) The natural history of factor VIII inhibitors in patients with Hemophilia A. In: Hoyer LW (ed) „Factor VIII Inhibitors. “ New York: Alan R Liss, Inc, p 19
Ikkala E, Simonen O (1971) Factor VIII inhibitors and the use of blood products in patients with haemophilia A. Scand J Haemat 8:16–20
Kasper CK (1973) Incidence and course of inhibitors among patients with classic haemophilia. Thrombo Diath Haemorrh 30:263–271
Schwartz RS, Abildgaard CF, Aledort LM et al (1990) Human recombinant DNA-derived antihemophilic factor (F VIII) in the treatment of hemophilia A. N Engl J Med 323:1799–1805
Schwarzinger I, Pabinger I, Korninger C et al (1987) Incidence of Inhibitors in Patients with Severe and Moderate Hemophilia A Treated with Factor VIII Concentrates. American J of Hematology 24:241–245
Strauss HS (1969) Aquired circulating anticoagulants in hemophilia A. N Engl J Med 281:886–873
Allain JP, Frommel D (1976) Antibodies to Factor VIII. V. Patterns of Immune Response to Factor VIII in Hemophilia A. Blood 47:973
Ruggeri ZM (1977). Natural history of 39 factor VIII inhibitors in hemophilias. In: Workshop on Inhibitors of Factors VIII and IX. Facultas-Verlag Wien, p 45–48
Shapiro SS (1979) Antibodies to blood coagulation factors. Clinics in Haematology 8:207–214
Shapiro SS, Hultin M (1975) Acquired inhibitors to the blood coagulation factors. Semin Thromb Hemost 1:336
Langdell RD, Wagner RH, Brinkhous KM (1953) Effect of antihaemophilic factor on one-stage-clotting test: A presumptive test for haemophilia and a simple one-stage antihaemophilic factor assay procedure. J Lab Clin Med 41:637–645
Kasper CK, Aledort LM, Counts RB et al (1975) A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 34:869
Kaplan EL, Meier (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481
Ikkala E, Helske T, Myllyläg G et al (1982) Changes in the life-expectancy of patients with severe haemophilia A in Finland in 1930–1979. Br J Haematol 52:7–12
Rizza CR, Spooner RJD (1983) Treatment of hemophilia and related disorders in Britain and Northern Ireland during 1976–1980: Report on behalf of the directors of hemophilia centres in the United Kingdom. Br Med J 286:929
Larsson SA (1985) Life expectancy of Swedish haemophiliacs 1831–1980. Br J Haematol 59:593–602
Rosendaal FR, Varekamp I, Smit C et al (1989) Mortality and causes of death in Dutch hemophiliacs 1973–1986. Br J Haematol 71:71–76
Mc Millan CW, Shapiro SS, Whitehurst D et al (1988) The natural history of factor VIII inhibitors in patients with hemophilia A: A national cooperative study. II. Observations on the initial development of factor VIII: C inhibitors. N Engl J Med 71:344–348
Rasi V, Ikkala E (1990) Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome. Br J Haematol 76:369–371
Shapiro SS (1984) Markers for the Factor VIII Antibody Response in Hemophilia A. Scand J Haematol-Suppl 40:33, 181 –185
Kesteven PJ, Holland LJ, Lawrie AS et al (1984) Inhibitor to Faktor VIII in Mild Hemophilia. Thromb Haemostas 52:50–52
Stenbjerg S, Ingerslev J, Zachariae E (1984). Factor VIII inhibitor treatment with high doses of factor VIII. Thrombosis Research 34:533–539
Kreuz W, Ehrenforth S, Scharrer I et al (1991) Factor VIII inhibitors in children with haemophilia. Long-term longitudinal results of dose-dependent induced immunotolerance. Annals of Hematol 62: A 46
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Ehrenforth, S., Kreuz, W., Linde, R., Menzer, D., Beeg, T., Scharrer, I. (1992). Inzidenz der Faktor VIII-Hemmkörperentwicklung bei Hämophilie-Patienten und kumulatives Risiko in Abhängigkeit von Alter und Substitutionstherapie. Ergebnisse einer 15jährigen Longitudinal-Studie. In: Landbeck, G., Scharrer, I., Schramm, W. (eds) 22. Hämophilie-Symposion Hamburg 1991. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77881-0_35
Download citation
DOI: https://doi.org/10.1007/978-3-642-77881-0_35
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-56096-8
Online ISBN: 978-3-642-77881-0
eBook Packages: Springer Book Archive